A single-dose strategy for immunization with live attenuated vaccines is an effective option before treatment initiation in multiple sclerosis patients
Carvajal, René (Hospital Universitari Vall d'Hebron)
Tur, Carmen (Hospital Universitari Vall d'Hebron)
Martínez Gómez, Xavier (Hospital Universitari Vall d'Hebron)
Bollo, Luca (Hospital Universitari Vall d'Hebron)
Esperalba, Juliana (Hospital Universitari Vall d'Hebron)
Rodriguez, Marta (Hospital Universitari Vall d'Hebron)
Pappolla, Agustin (Hospital Universitari Vall d'Hebron)
Cobo-Calvo, Álvaro (Hospital Universitari Vall d'Hebron)
Carbonell, Pere (Hospital Universitari Vall d'Hebron)
Borras-Bemejo, Blanca (Hospital Universitari Vall d'Hebron)
Río, Jordi (Hospital Universitari Vall d'Hebron)
Castilló, Joaquín (Vall d'Hebron Institut de Recerca (VHIR))
Braga, Nathane (Hospital Universitari Vall d'Hebron)
Mongay-Ochoa, Neus (Hospital Universitari Vall d'Hebron)
Rodrigo Pendas, Jose Angel (Hospital Universitari Vall d'Hebron)
Vidal-Jordana, Angela (Hospital Universitari Vall d'Hebron)
Arrambide, Georgina (Hospital Universitari Vall d'Hebron)
Zabalza, Ana (Hospital Universitari Vall d'Hebron)
Midaglia, Luciana (Hospital Universitari Vall d'Hebron)
Galan, Ingrid (Hospital Universitari Vall d'Hebron)
Comabella López, Manuel (Hospital Universitari Vall d'Hebron)
Sastre-Garriga, Jaume (Hospital Universitari Vall d'Hebron)
Tintoré, Mar (Hospital Universitari Vall d'Hebron)
Otero-Romero, Susana (Hospital Universitari Vall d'Hebron)
Universitat Autònoma de Barcelona

Data:	2023
Resum:	Mumps-Measles-Rubella (MMR) and Varicella zoster vaccines (VAR) are live attenuated vaccines, usually administered in a two-dose scheme at least 4 weeks apart. However, single-dose immunization schemes may also be effective and can reduce delays in immunosuppressive treatment initiation in patients with multiple sclerosis (pwMS) who need to be immunized. To evaluate the immunogenicity of a single-dose attempt (SDA) versus the standard immunization scheme (SIS) with VAR and/or MMR in pwMS. Retrospective observational study in pwMS vaccinated against VAR and/or MMR. We compared seroprotection rates and antibody geometric mean titers (GMTs) between the two strategies. Ninety-six patients were included. Thirty-one patients received VAR and 67 MMR. In the SDA group, the seroprotection rate was 66. 7% (95% confidence interval (CI): 53. 3-78. 3) versus 97. 2% (95% CI: 85. 5-99. 9) in the SIS (p < 0. 001). For the seroprotected patients, GMTs were similar for both schemes. An SDA of VAR and/or MMR vaccines could be sufficient to protect almost two-thirds of patients. Testing immunogenicity after a single dose of VZ and/or MMR could be included in routine clinical practice to achieve rapid immunization.
Ajuts:	Instituto de Salud Carlos III PI19/01606
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Multiple sclerosis ; Vaccination ; Live attenuated vaccine ; Disease-modifying therapy ; Infections
Publicat a:	Multiple sclerosis, Vol. 29 (september 2023) , p. 1841-1848, ISSN 1477-0970

DOI: 10.1177/13524585231200303
PMID: 37728389

8 p, 719.5 KB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats